Pineda Torra Inés, Claudel Thierry, Duval Caroline, Kosykh Vladimir, Fruchart Jean-Charles, Staels Bart
U.545 Institut National de la Santé et de la Recherche Médicale, Département d'Athérosclérose, Institut Pasteur de Lille, 59019 Lille, France.
Mol Endocrinol. 2003 Feb;17(2):259-72. doi: 10.1210/me.2002-0120.
Peroxisome proliferator-activated receptor alpha (PPARalpha) is a nuclear receptor that controls lipid and glucose metabolism and exerts antiinflammatory activities. PPARalpha is also reported to influence bile acid formation and bile composition. Farnesoid X receptor (FXR) is a bile acid-activated nuclear receptor that mediates the effects of bile acids on gene expression and plays a major role in bile acid and possibly also in lipid metabolism. Thus, both PPARalpha and FXR appear to act on common metabolic pathways. To determine the existence of a molecular cross-talk between these two nuclear receptors, the regulation of PPARalpha expression by bile acids was investigated. Incubation of human hepatoma HepG2 cells with the natural FXR ligand chenodeoxycholic acid (CDCA) as well as with the nonsteroidal FXR agonist GW4064 resulted in a significant induction of PPARalpha mRNA levels. In addition, hPPARalpha gene expression was up-regulated by taurocholic acid in human primary hepatocytes. Cotransfection of FXR/retinoid X receptor in the presence of CDCA led to up to a 3-fold induction of human PPARalpha promoter activity in HepG2 cells. Mutation analysis identified a FXR response element in the human PPARalpha promoter (alpha-FXR response element (alphaFXRE)] that mediates bile acid regulation of this promoter. FXR bound the alphaFXRE site as demonstrated by gel shift analysis, and CDCA specifically increased the activity of a heterologous promoter driven by four copies of the alphaFXRE. In contrast, neither the murine PPARalpha promoter, in which the alphaFXRE is not conserved, nor a mouse alphaFXRE-driven heterologous reporter, were responsive to CDCA treatment. Moreover, PPARalpha expression was not regulated in taurocholic acid-fed mice. Finally, induction of hPPARalpha mRNA levels by CDCA resulted in an enhanced induction of the expression of the PPARalpha target gene carnitine palmitoyltransferase I by PPARalpha ligands. In concert, these results demonstrate that bile acids stimulate PPARalpha expression in a species-specific manner via a FXRE located within the human PPARalpha promoter. These results provide molecular evidence for a cross-talk between the FXR and PPARalpha pathways in humans.
过氧化物酶体增殖物激活受体α(PPARα)是一种核受体,可控制脂质和葡萄糖代谢并发挥抗炎活性。据报道,PPARα还会影响胆汁酸的形成和胆汁成分。法尼酯X受体(FXR)是一种胆汁酸激活的核受体,可介导胆汁酸对基因表达的影响,并在胆汁酸以及可能在脂质代谢中起主要作用。因此,PPARα和FXR似乎都作用于共同的代谢途径。为了确定这两种核受体之间是否存在分子相互作用,研究了胆汁酸对PPARα表达的调节作用。用人肝癌HepG2细胞与天然FXR配体鹅去氧胆酸(CDCA)以及非甾体FXR激动剂GW4064孵育,导致PPARα mRNA水平显著升高。此外,在人原代肝细胞中,牛磺胆酸上调了hPPARα基因的表达。在CDCA存在的情况下,FXR/视黄酸X受体的共转染导致HepG2细胞中人类PPARα启动子活性提高了3倍。突变分析在人PPARα启动子中鉴定出一个FXR反应元件(α-FXR反应元件(αFXRE)),该元件介导该启动子的胆汁酸调节。凝胶迁移分析表明FXR与αFXRE位点结合,并且CDCA特异性增加了由四个αFXRE拷贝驱动的异源启动子的活性。相比之下,αFXRE不保守的小鼠PPARα启动子以及小鼠αFXRE驱动的异源报告基因均对CDCA处理无反应。此外,在牛磺胆酸喂养的小鼠中,PPARα的表达不受调节。最后,CDCA诱导hPPARα mRNA水平导致PPARα配体对PPARα靶基因肉碱棕榈酰转移酶I表达的诱导增强。总之,这些结果表明胆汁酸通过位于人PPARα启动子内的FXRE以物种特异性方式刺激PPARα表达。这些结果为人类FXR和PPARα途径之间的相互作用提供了分子证据。